XML 22 R10.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Financial Instruments and Derivative Instruments | 6 Months Ended
--- | ---
Jun. 30, 2013
Financial Instruments and Derivative Instruments |
Financial Instruments and Derivative Instruments | 4. Financial Instruments and Derivative Instruments The Company measures certain financial assets and liabilities at fair value on a recurring basis, including deferred compensation plan assets and related liability, and contingent consideration. There were no designated cash flow hedges as of June 30, 2013 and December 31, 2012. The fair values of these certain financial assets and liabilities were determined using the following inputs at June 30, 2013 and December 31, 2012:
|  | Fair Value Measurements at June 30, 2013 Using: |
|  |  |  | Quoted Prices in Active Markets for Identical Assets |  | Significant Other Observable Inputs |  | Significant Unobservable Inputs |
|  | Total |  | (Level 1) |  | (Level 2) |  | (Level 3) |
|  | (in millions) |
Assets |  |  |  |  |  |  |  |  |
Plan asset for deferred compensation(1) |  | $ | 4.3 |  | $ | 4.3 |  | $ | — |  | $ | — |
Total assets |  | $ | 4.3 |  | $ | 4.3 |  | $ | — |  | $ | — |
Liabilities |  |  |  |  |  |  |  |  |
Plan liability for deferred compensation(2) |  | $ | 4.3 |  | $ | 4.3 |  | $ | — |  | $ | — |
Contingent consideration(3) |  | 3.8 |  | — |  | — |  | 3.8 |
Total liabilities |  | $ | 8.1 |  | $ | 4.3 |  | $ | — |  | $ | 3.8 |
|  | Fair Value Measurements at December 31, 2012 Using: |
|  |  |  | Quoted Prices in Active Markets for Identical Assets |  | Significant Other Observable Inputs |  | Significant Unobservable Inputs |
|  | Total |  | (Level 1) |  | (Level 2) |  | (Level 3) |
|  | (in millions) |
Assets |  |  |  |  |  |  |  |  |
Plan asset for deferred compensation(1) |  | $ | 4.2 |  | $ | 4.2 |  | $ | — |  | $ | — |
Total assets |  | $ | 4.2 |  | $ | 4.2 |  | $ | — |  | $ | — |
Liabilities |  |  |  |  |  |  |  |  |
Plan liability for deferred compensation(2) |  | $ | 4.2 |  | $ | 4.2 |  | $ | — |  | $ | — |
Contingent consideration(3) |  | 5.2 |  | — |  | — |  | 5.2 |
Total liabilities |  | $ | 9.4 |  | $ | 4.2 |  | $ | — |  | $ | 5.2 |
(1) Included in other, net on the Company’s consolidated balance sheet. (2) Included in accrued compensation and benefits on the Company’s consolidated balance sheet. (3) Included in other noncurrent liabilities and accrued expenses and other liabilities on the Company’s consolidated balance sheet. The table below provides a summary of the changes in fair value of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the period December 31, 2012 to June 30, 2013.
|  | Balance |  | Purchases, |  | Total realized and unrealized (gains) losses included in: |  | Balance |
|  | December 31, 2012 |  | sales, settlements, net |  | Earnings |  | Comprehensive income |  | June 30, 2013 |
|  | (in millions) |
Contingent consideration |  | $ | 5.2 |  | $ | (1.2 | ) | $ | 0.1 |  | $ | (0.3 | ) | $ | 3.8 |
In connection with the tekmar acquisition in January 2012, a contingent liability of $5.1 million was recognized as the estimate of the acquisition date fair value of the contingent consideration. This liability was classified as Level 3 under the fair value hierarchy as it was based on the probability of achievement of a future performance metric as of the date of the acquisition, which was not observable in the market. Failure to meet the performance metrics would reduce this liability to zero, while complete achievement would increase this liability to the full remaining purchase price of $8.2 million. A portion of the contingent consideration was paid out during the period ended June 30, 2013, in the amount of $1.2 million, based on performance metrics achieved in fiscal year 2012. The contingent liability was increased by $0.1 million during the period based on performance metrics achieved to date. Short-term investment securities as of December 31, 2012 consist of a certificate of deposit with a remaining maturity of greater than three months at the date of purchase, for which the carrying amount is a reasonable estimate of fair value. There were no short-term investment securities as of June 30, 2013. Cash equivalents consist of instruments with remaining maturities of three months or less at the date of purchase and consist primarily of certificates of deposit and money market funds, for which the carrying amount is a reasonable estimate of fair value. The Company uses financial instruments from time to time to enhance its ability to manage risk, including foreign currency and commodity pricing exposures, which exist as part of its ongoing business operations. The use of derivatives exposes the Company to counterparty credit risk for nonperformance and to market risk related to changes in currency exchange rates and commodity prices. The Company manages its exposure to counterparty credit risk through diversification of counterparties. The Company’s counterparties in derivative transactions are substantial commercial banks with significant experience using such derivative instruments. The impact of market risk on the fair value and cash flows of the Company’s derivative instruments is monitored and the Company restricts the use of derivative financial instruments to hedging activities. The Company does not enter into contracts for trading purposes nor does the Company enter into any contracts for speculative purposes. The use of derivative instruments is approved by senior management under written guidelines. The Company has exposure to a number of foreign currency rates, including the Canadian Dollar, the Euro, the Chinese Yuan and the British Pound. To manage this risk, the Company generally uses a layering methodology whereby at the end of any quarter the Company has generally entered into forward exchange contracts which hedge approximately 50% of the projected intercompany purchase transactions for the next twelve months. The Company primarily uses this strategy for purchases between Canada and the U.S. The average volume of contracts can vary but generally is approximately $4 million to $15 million in open contracts at the end of any given quarter. At June 30, 2013, the Company had contracts for notional amounts aggregating to $4.5 million. The Company accounts for the forward exchange contracts as an economic hedge. Realized and unrealized gains and losses on the contracts are recognized in other (income) expense in the consolidated statement of operations. These contracts do not subject the Company to significant market risk from exchange movement because they offset gains and losses on the related foreign currency denominated transactions. Fair Value The carrying amounts of cash and cash equivalents, short-term investments, trade receivables and trade payables approximate fair value because of the short maturity of these financial instruments. The fair values of the Company’s 5.85% senior notes due 2016, and 5.05% senior notes due 2020, are based on a discounted cash flow model using comparable industrial companies, the Company’s credit metrics, the Company’s size, as well as current market interest rates quoted in active markets and are classified within Level 2 of the valuation hierarchy. The fair value of the Company’s variable rate debt approximates its carrying value. The carrying amount and the estimated fair market value of the Company’s long-term debt, including the current portion, are as follows:
|  | June 30, |  | December 31, |
|  | 2013 |  | 2012 |
|  | (in millions) |
Carrying amount |  | $ | 308.4 |  | $ | 384.6 |
Estimated fair value |  | $ | 337.1 |  | $ | 420.8 |

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration